Apolipoprotein E genetic polymorphism, remnant lipoproteins, and nephropathy in type 2 diabetic patients.

BACKGROUND We previously showed that the apolipoprotein (apo) Eepsilon2 allele is associated with the progression of diabetic nephropathy. The aim of the present study is to further investigate the association between apo E genetic polymorphism, plasma lipid levels (particularly remnant lipoproteins), and diabetic nephropathy. SUBJECTS AND METHODS One hundred fifty-eight patients with type 2 diabetes who had a duration of diabetes longer than 10 years were divided into the three apo E groups: apo E2 (n = 22), E3/3 (n = 102), and E4 (n = 34). Plasma levels of lipids and remnant lipoproteins were measured. The effect of apo E2 triglyceride (TG)-rich lipoproteins, including remnant lipoproteins, on the accumulation of cholesteryl esters by human mesangial cells (HMCs) was estimated by measuring the stimulation of radioactive carbon-labeled oleate incorporation into cholesteryl esters. RESULTS The frequency of overt nephropathy was significantly greater in apo E2 patients with diabetes (59.1%) than apo E3/3 (34.3%) or apo E4 patients (8.8%), and the frequency of normoalbuminuria was significantly greater in apo E4 patients with diabetes (67.6%) than apo E3/3 (34.3%) or apo E2 patients (4.5%). Logistical regression analysis showed that odds ratios of apo E2 and apo E4 genotypes for the presence of overt nephropathy were 10.179 (P = 0.0349) and 0.129 (P = 0.0028), respectively. Plasma TG and remnant-like lipoprotein particle cholesterol levels were significantly greater in apo E2 patients and significantly lower in apo E4 patients than apo E3/3 patients. Apo E2 TG-rich lipoproteins stimulated the accumulation of cholesteryl esters by HMCs significantly more than apo E3/3 or apo E4 TG-rich lipoproteins. CONCLUSION Apo E2 is a positive factor and apo E4 is a negative factor for diabetic nephropathy. Apo E2 TG-rich lipoproteins, including remnant lipoproteins, affected HMCs. Remnant lipoproteins may have an important role in the progression of diabetic nephropathy.

[1]  I. Makino,et al.  Increased frequency of apolipoprotein ε2 allele in non‐insulin dependent diabetic (NIDDM) patients with nephropathy , 1995 .

[2]  M. Laakso,et al.  Apolipoprotein E phenotype is related to macro- and microangiopathy in patients with non-insulin-dependent diabetes mellitus. , 1993, Atherosclerosis.

[3]  T. Taniguchi,et al.  Elevated remnant-like lipoprotein particles in impaired glucose tolerance and type 2 diabetic patients. , 1999, Diabetes care.

[4]  Z. Varghese,et al.  LIPID NEPHROTOXICITY IN CHRONIC PROGRESSIVE GLOMERULAR AND TUBULO-INTERSTITIAL DISEASE , 1982, The Lancet.

[5]  B. Kasiske,et al.  Lipids and progressive glomerulosclerosis. A model analogous to atherosclerosis. , 1988, American journal of nephrology.

[6]  S. J. Kim,et al.  Association between apolipoprotein E polymorphism and macroalbuminuria in patients with non-insulin dependent diabetes mellitus. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  I. Makino,et al.  Triglyceride-rich lipoproteins from apolipoprotein E3/2 subjects with hypertriglyceridemia enhance cholesteryl ester synthesis in human macrophages. , 1997, Atherosclerosis.

[8]  J. Oram.  Receptor-mediated transport of cholesterol between cultured cells and high-density lipoproteins. , 1986, Methods in enzymology.

[9]  K. Nakajima,et al.  Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. , 1993, Clinica chimica acta; international journal of clinical chemistry.

[10]  J. Diamond,et al.  Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. , 1991, Kidney international. Supplement.

[11]  K. Watanabe,et al.  Apolipoprotein E Polymorphism and Hyperlipemia in Type II Diabetics , 1986, Diabetes.

[12]  J. Todd,et al.  Association of Apolipoprotein ε2 Allele With Diabetic Nephropathy in Caucasian Subjects With IDDM , 1998, Diabetes.

[13]  D. Porte,et al.  Hypertriglyceridemia. A metabolic consequence of chronic renal failure. , 1968, The New England journal of medicine.

[14]  R J Havel,et al.  Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes. , 1982, Journal of lipid research.

[15]  K. Watanabe,et al.  A racial difference in apolipoprotein E allele frequencies between the Japanese and Caucasian populations , 1986, Clinical genetics.

[16]  R. Gregg,et al.  Abnormal in vivo metabolism of apolipoprotein E4 in humans. , 1986, The Journal of clinical investigation.

[17]  C. Blum,et al.  Apolipoprotein E synthesis in human kidney, adrenal gland, and liver. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[18]  A. Krolewski,et al.  Apolipoprotein E genotypes and risk of diabetic nephropathy. , 1996, Journal of the American Society of Nephrology : JASN.

[19]  Baig Ar,et al.  Sex-chromatin values in rat epithelium. , 1967 .

[20]  R. Mahley,et al.  Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.

[21]  T. Sato,et al.  Apolipoprotein-E2 and hyperlipoproteinemia in noninsulin-dependent diabetes mellitus. , 1989, The Journal of clinical endocrinology and metabolism.

[22]  M. Arakawa,et al.  Immunohistological localization of apolipoproteins in the glomeruli in renal disease: specifically apoB and apoE. , 1991, Clinical nephrology.

[23]  H. Mulec,et al.  Relation between serum cholesterol and diabetic nephropathy , 1990, The Lancet.

[24]  K. Watanabe,et al.  A rapid flat gel isoelectric focusing method for the determination of apolipoprotein E phenotypes and its application. , 1985, Clinica chimica acta; international journal of clinical chemistry.

[25]  P. Nestel,et al.  Increased lipoprotein-remnant formation in chronic renal failure. , 1982, The New England journal of medicine.

[26]  R. Mahley,et al.  Cholesteryl ester accumulation in macrophages resulting from receptor-mediated uptake and degradation of hypercholesterolemic canine beta-very low density lipoproteins. , 1980, The Journal of biological chemistry.

[27]  R. Havel,et al.  Properties of an apolipoprotein E-enriched fraction of triglyceride-rich lipoproteins isolated from human blood plasma with a monoclonal antibody to apolipoprotein B-100. , 1992, Journal of lipid research.

[28]  C. Sing,et al.  Apolipoprotein E polymorphism and atherosclerosis. , 1988, Arteriosclerosis.

[29]  K. Watanabe,et al.  Apolipoprotein E alleles and hyperlipoproteinemia in Japan , 1988, Clinical genetics.

[30]  E. Werle,et al.  Apolipoprotein E Polymorphism and Renal Function in German Type 1 and Type 2 Diabetic Patients , 1998, Diabetes Care.

[31]  P. Kincaid‐smith,et al.  Foam cells in the renal glomerulus , 1969, The Journal of pathology.

[32]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[33]  D. T. Vernier,et al.  Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. , 1990, Journal of lipid research.

[34]  G. Utermann,et al.  Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man , 1977, Nature.

[35]  M. Eto,et al.  Increased Frequency of Apolipoprotein ∈4 Allele in Type II Diabetes With Hypercholesterolemia , 1987, Diabetes.

[36]  K. Watanabe,et al.  Reciprocal effects of apolipoprotein E alleles (ε2 AND ε4) on plasma lipid levels in normolipidemic subjects , 1986 .

[37]  I. Makino,et al.  Apolipoprotein E2, renal failure and lipid abnormalities in non-insulin-dependent diabetes mellitus. , 1994, Atherosclerosis.

[38]  T. Matsumura,et al.  Human β-migrating very low density lipoprotein induces foam cell formation in human mesangial cells , 1997 .

[39]  I. Makino,et al.  Apolipoprotein E allele frequencies in non-insulin-dependent diabetes mellitus with hypertriglyceridemia (type IIb, III, IV, and V hyperlipoproteinemia). , 1991, Metabolism: clinical and experimental.

[40]  M. Shichiri,et al.  Effect of plasmapheresis on familial type III hyperlipoproteinemia associated with glomerular lipidosis, nephrotic syndrome and diabetes mellitus , 1990 .

[41]  D. Moczulski,et al.  APOE polymorphisms and the development of diabetic nephropathy in type 1 diabetes: results of case-control and family-based studies. , 2000, Diabetes.

[42]  F. Gejyo,et al.  Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.